Reforming oncology reimbursement is one method that could increase incentives to manufacturers and subsequently reduce drug shortages, according to testimony at a Senate Finance Committee hearing.
The hearing addressed causes of the recent drug shortages. About 30% of the drugs in short supply are oncology products.
Oncology drugs are reimbursed according to average sales price and an additional 6% markup that covers practice costs as a result of the Medicare Modernization Act in 2003, according to a perspective published last month in the New England Journal of Medicine. The authors said in the perspective that oncologists have incentive to use brand-name drugs that will provide a higher margin.
Read more: Changing oncology reimbursement could cut drug shortages, lawmakers told
Source: Modern Healthcare
Health Equity and Access Weekly Roundup: December 2, 2023
December 2nd 2023The Center on Health Equity and Access highlights the most recent updates in the realm of health equity, including news, research findings, and initiatives focused on mitigating health care disparities and enhancing overall access to quality care.
Read More